Palma, Flavio R. http://orcid.org/0000-0003-4350-2708
Gantner, Benjamin N. http://orcid.org/0000-0002-6947-7670
Sakiyama, Marcelo J.
Kayzuka, Cezar
Shukla, Sanjeev http://orcid.org/0000-0003-3361-0588
Lacchini, Riccardo
Cunniff, Brian
Bonini, Marcelo G. http://orcid.org/0000-0003-1193-1428
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (R01ES028149, R56033398)
U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL163820)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA216882)
Article History
Received: 13 September 2023
Revised: 1 November 2023
Accepted: 21 November 2023
First Online: 11 December 2023
Competing interests
: BC has a financial interest (research support, equity and consultant fees) in RS Oncology, a clinical stage biotechnology company developing therapies targeting mitochondrial activity and redox signaling in cancer.